Cancer: Gut microbiome provides prognosis for therapy

Cancer patients respond differently to therapies. Our latest research has found that the success of the classical treatment methods depends on the composition of the microbiome in the gut, in particular several key specific bacteria.

Published in Microbiology

Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Around one out of six deaths worldwide is related to cancer. The best known treatment methods include chemotherapy and immunotherapy. These therapies work by inhibiting the further division of cancer cells or by supporting the immune system in killing the tumour cells. However, despite today's well-developed anti-cancer therapies, their efficiency is not as high as desired.

We know that the intestinal microbiome plays an important role in therapeutic success. So all the microorganisms living in our gut can somehow influence the outcome of therapeutic measures in cancer treatment. To this end, we analysed metagenomic sequencing data from the stool samples of cancer patients treated with chemotherapy or a combination of chemotherapy and immunotherapy. The experimental group consisted of patients with eight different types of cancer – a novelty since comparable studies have so far concentrated on only one type of cancer.

Fig. 1. Human gut microbiota is associated with patients response to anti-cancer treatment.

Nevertheless, we were able to identify some common features in the stool analysis. The intestinal microbiomes of those cancer patients who responded well to the therapy show a greater microbial diversity. In addition, the bacterial species found in their intestine differ from those of patients who responded less well to therapy. More specifically, the species Bacteroides ovatus and Bacteroides xylanisolvens have a positive effect on the course of therapy, whereas Clostridium symbiosum and Ruminococcus gnavus were found in higher amount in the patients whose anti-cancer therapy was less successful. With the help of these findings, our team has developed a prediction model based on machine learning. This model makes it possible to calculate the probability of successful anti-cancer treatment before therapy begins, regardless of the type of cancer. Moreover, the model proved to be highly accurate in another patient group.

We also tested the effect of these responder bacteria (Bacteroides ovatus and Bacteroides xylanisolvens) in experimental mice with lung cancer induced. Feeding the mice with those bacteria helped increase the efficacy of erlotinib (an anti-cancer drug) and further reduced the tumour volume by 46% compared to the control. Such enhancement of chemotherapy efficacy may be achieved by synergistically upregulating the expression of chemokines, CXCL9 and IFN-γ, involved in the recruitment of immune T cells.

Fig. 2. Increased anti-tumor efficacy of chemotherapy in the presence of B. ovatusand B. xylanisolvens. (A) Experimental design: Male 6-week C57BL6/N mice (n=5-8) were treated with antibiotic cocktail in drinking water for 1 week before bacterial oral gavage. Control PBS, B. ovatus and B. xylanisolvens, and C. symbiosum and R. gnavus were orally gavaged into mice 1 week prior to tumor cell inoculation. A total of 10Lewis lung cancer cells in 200 µl PBS were subcutaneously injected into the mice to induce tumor formation. Mice were treated with erlotinib(60 mg/kg body weight) once the tumor size reached approximately 250-500 mm3. Time in days is relative to tumor cells injection. (B) Tumor size measurement at day 14. (C) Tumor growth curve after Lewis lung carcinoma cellinoculation. Dark dots indicate the application of erlotinib.

Our study suggests a predictable impact of specific members of the gut microbiota on tumour growth and cancer treatment outcomes with implications for prognosis. For better therapeutic outcomes, the administration of specific probiotic bacteria could be a potential supplemental treatment in combination with anticancer therapies.

For more details please check: https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-020-00811-2

Predictable modulation of cancer treatment outcomes by the gut microbiotaMicrobiome 8, 28 (2020)

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Microbiology
Life Sciences > Biological Sciences > Microbiology
  • Microbiome Microbiome

    This journal hopes to integrate researchers with common scientific objectives across a broad cross-section of sub-disciplines within microbial ecology. It covers studies of microbiomes colonizing humans, animals, plants or the environment, both built and natural or manipulated, as in agriculture.

Related Collections

With Collections, you can get published faster and increase your visibility.

Harnessing plant microbiomes to improve performance and mechanistic understanding

This is a Cross-Journal Collection with Microbiome, Environmental Microbiome, npj Science of Plants, and npj Biofilms and Microbiomes. Please click here to see the collection page for npj Science of Plants and npj Biofilms and Microbiomes.

Modern agriculture needs to sustainably increase crop productivity while preserving ecosystem health. As soil degradation, climate variability, and diminishing input efficiency continue to threaten agricultural outputs, there is a pressing need to enhance plant performance through ecologically-sound strategies. In this context, plant-associated microbiomes represent a powerful, yet underexploited, resource to improve plant vigor, nutrient acquisition, stress resilience, and overall productivity.

The plant microbiome—comprising bacteria, fungi, and other microorganisms inhabiting the rhizosphere, endosphere, and phyllosphere—plays a fundamental role in shaping plant physiology and development. Increasing evidence demonstrates that beneficial microbes mediate key processes such as nutrient solubilization and uptake, hormonal regulation, photosynthetic efficiency, and systemic resistance to (a)biotic stresses. However, to fully harness these capabilities, a mechanistic understanding of the molecular dialogues and functional traits underpinning plant-microbe interactions is essential.

Recent advances in multi-omics technologies, synthetic biology, and high-throughput functional screening have accelerated our ability to dissect these interactions at molecular, cellular, and system levels. Yet, significant challenges remain in translating these mechanistic insights into robust microbiome-based applications for agriculture. Core knowledge gaps include identifying microbial functions that are conserved across environments and hosts, understanding the signaling networks and metabolic exchanges between partners, and predicting microbiome assembly and stability under field conditions.

This Research Topic welcomes Original Research, Reviews, Perspectives, and Meta-analyses that delve into the functional and mechanistic basis of plant-microbiome interactions. We are particularly interested in contributions that integrate molecular microbiology, systems biology, plant physiology, and computational modeling to unravel the mechanisms by which microbial communities enhance plant performance and/or mechanisms employed by plant hosts to assemble beneficial microbiomes. Studies ranging from controlled experimental systems to applied field trials are encouraged, especially those aiming to bridge the gap between fundamental understanding and translational outcomes such as microbial consortia, engineered strains, or microbiome-informed management practices.

Ultimately, this collection aims to advance our ability to rationally design and apply microbiome-based strategies by deepening our mechanistic insight into how plants select beneficial microbiomes and in turn how microbes shape plant health and productivity.

This collection is open for submissions from all authors on the condition that the manuscript falls within both the scope of the collection and the journal it is submitted to.

All submissions in this collection undergo the relevant journal’s standard peer review process. Similarly, all manuscripts authored by a Guest Editor(s) will be handled by the Editor-in-Chief of the relevant journal. As an open access publication, participating journals levy an article processing fee (Microbiome, Environmental Microbiome). We recognize that many key stakeholders may not have access to such resources and are committed to supporting participation in this issue wherever resources are a barrier. For more information about what support may be available, please visit OA funding and support, or email OAfundingpolicy@springernature.com or the Editor-in-Chief of the journal where the article is being submitted.

Collection policies for Microbiome and Environmental Microbiome:

Please refer to this page. Please only submit to one journal, but note authors have the option to transfer to another participating journal following the editors’ recommendation.

Collection policies for npj Science of Plants and npj Biofilms and Microbiomes:

Please refer to npj's Collection policies page for full details.

Publishing Model: Open Access

Deadline: Jun 01, 2026

Microbiome and Reproductive Health

Microbiome is calling for submissions to our Collection on Microbiome and Reproductive Health.

Our understanding of the intricate relationship between the microbiome and reproductive health holds profound translational implications for fertility, pregnancy, and reproductive disorders. To truly advance this field, it is essential to move beyond descriptive and associative studies and focus on mechanistic research that uncovers the functional underpinnings of the host–microbiome interface. Such studies can reveal how microbial communities influence reproductive physiology, including hormonal regulation, immune responses, and overall reproductive health.

Recent advances have highlighted the role of specific bacterial populations in both male and female fertility, as well as their impact on pregnancy outcomes. For example, the vaginal microbiome has been linked to preterm birth, while emerging evidence suggests that gut microbiota may modulate reproductive hormone levels. These insights underscore the need for research that explores how and why these microbial influences occur.

Looking ahead, the potential for breakthroughs is immense. Mechanistic studies have the power to drive the development of microbiome-based therapies that address infertility, improve pregnancy outcomes, and reduce the risk of reproductive diseases. Incorporating microbiome analysis into reproductive health assessments could transform clinical practice and, by deepening our understanding of host–microbiome mechanisms, lay the groundwork for personalized medicine in gynecology and obstetrics.

We invite researchers to contribute to this Special Collection on Microbiome and Reproductive Health. Submissions should emphasize functional and mechanistic insights into the host–microbiome relationship. Topics of interest include, but are not limited to:

- Microbiome and infertility

- Vaginal microbiome and pregnancy outcomes

- Gut microbiota and reproductive hormones

- Microbial influences on menstrual health

- Live biotherapeutics and reproductive health interventions

- Microbiome alterations as drivers of reproductive disorders

- Environmental factors shaping the microbiome

- Intergenerational microbiome transmission

This Collection supports and amplifies research related to SDG 3, Good Health and Well-Being.

All submissions in this collection undergo the journal’s standard peer review process. As an open access publication, this journal levies an article processing fee (details here). We recognize that many key stakeholders may not have access to such resources and are committed to supporting participation in this issue wherever resources are a barrier. For more information about what support may be available, please visit OA funding and support, or email OAfundingpolicy@springernature.com or the Editor-in-Chief.

Publishing Model: Open Access

Deadline: Jun 16, 2026